CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −7,215 | $106.25 | $767K | 17,309 |
| 2026-09-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −13,309 | $106.74 | $1.4M | 4,000 |
| 2026-09-01 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 56,776 | ||
| 2026-09-01 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,249 | 41,676 | ||
| 2026-09-01 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,375 | 87,500 | ||
| 2026-08-19 | Read Simon Director | Option exercise 10b5-1 | +2,778 | $18.36 | $51K | 2,778 |
| 2026-08-19 | Read Simon Director | Sale 10b5-1 | −2,778 | $117.55 | $327K | 0 |
| 2026-08-19 | Read Simon Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,778 | 19,445 | ||
| 2026-08-13 | Veness Adam M SVP, General Counsel and Sec. | Option exercise | +15,000 | $18.17 | $273K | 15,000 |
| 2026-08-13 | Veness Adam M SVP, General Counsel and Sec. | Option exercise · Stock Option (Right to Buy) | −15,000 | 73,240 | ||
| 2026-08-10 | McGeorge Anne Director | Option exercise 10b5-1 | +1,250 | $19.36 | $24K | 1,250 |
| 2026-08-10 | McGeorge Anne Director | Option exercise 10b5-1 | +6,500 | $11.20 | $73K | 7,750 |
| 2026-08-10 | McGeorge Anne Director | Sale 10b5-1 | −1,450 | $107.58 | $156K | 6,300 |
| 2026-08-10 | McGeorge Anne Director | Sale 10b5-1 | −2,800 | $108.38 | $303K | 3,500 |
| 2026-08-10 | McGeorge Anne Director | Sale 10b5-1 | −1,800 | $109.30 | $197K | 1,700 |
| 2026-08-10 | McGeorge Anne Director | Sale 10b5-1 | −1,000 | $110.64 | $111K | 700 |
| 2026-08-10 | McGeorge Anne Director | Sale 10b5-1 | −700 | $111.41 | $78K | 0 |
| 2026-08-10 | McGeorge Anne Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,250 | 0 | ||
| 2026-08-10 | McGeorge Anne Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,500 | 0 | ||
| 2026-08-10 | Veness Adam M SVP, General Counsel and Sec. | Option exercise 10b5-1 | +16,167 | $17.88 | $289K | 16,167 |
Page 3 of 24 · 470 trades